Ilumya (tildrakizumab) vs Bimzelx (bimekizumab-bkzx)
Ilumya (tildrakizumab) vs Bimzelx (bimekizumab-bkzx)
Ilumya (tildrakizumab) and Bimzelx (bimekizumab-bkzx) are both biologic medications approved for the treatment of moderate to severe plaque psoriasis. Ilumya works by targeting IL-23, a cytokine involved in inflammatory processes, and is administered as an injection every 12 weeks after initial doses. Bimzelx, on the other hand, targets both IL-17A and IL-17F, which are also key cytokines in inflammation, and is given as an injection at a frequency determined by the prescribing physician based on the patient's needs. When deciding between the two, a patient should consider factors such as the specific cytokines targeted by the medication, dosing frequency, individual response to treatment, and potential side effects, in consultation with their healthcare provider.
Difference between Ilumya and Bimzelx
Metric | Ilumya (tildrakizumab) | Bimzelx (bimekizumab-bkzx) |
---|---|---|
Generic name | Tildrakizumab | Bimekizumab-bkzx |
Indications | Plaque psoriasis | Plaque psoriasis |
Mechanism of action | IL-23 inhibitor | IL-17A and IL-17F inhibitor |
Brand names | Ilumya | Bimzelx |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Upper respiratory infections, injection site reactions, diarrhea | Upper respiratory tract infections, oral candidiasis, injection site reactions |
Contraindications | Known hypersensitivity to tildrakizumab or excipients | Known hypersensitivity to bimekizumab or excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Sun Pharma | UCB Pharma |
Efficacy
Efficacy of Ilumya (Tildrakizumab) in Treating Psoriasis
Ilumya, known by its generic name tildrakizumab, is a medication approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine that plays a key role in the inflammation and development of psoriatic plaques. Clinical trials have demonstrated that Ilumya can lead to significant improvement in psoriasis symptoms. In these studies, patients treated with Ilumya showed marked reductions in Psoriasis Area and Severity Index (PASI) scores, a measure of the severity and extent of psoriasis, indicating its efficacy in managing the condition.
The pivotal phase 3 clinical trials, reSURFACE 1 and reSURFACE 2, have provided robust data on the efficacy of Ilumya. These trials have reported that a significant proportion of patients achieved at least a 75% reduction in PASI score (PASI 75) after 12 weeks of treatment, with continued improvement over time. Furthermore, some patients even achieved PASI 90 and PASI 100 responses, representing 90% and 100% improvements in PASI scores, respectively. These results suggest that Ilumya is highly effective in clearing psoriatic lesions and improving patients' quality of life.
Efficacy of Bimzelx (Bimekizumab-bkzx) in Treating Psoriasis
Bimzelx, with the generic name bimekizumab-bkzx, is another biologic therapy recently approved for the treatment of moderate to severe plaque psoriasis in adults. Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key pro-inflammatory cytokines involved in the pathogenesis of psoriasis. By targeting these cytokines, Bimzelx effectively reduces inflammation and the formation of psoriatic plaques. Clinical studies have shown that Bimzelx can lead to rapid and extensive skin clearance in patients with plaque psoriasis.
The efficacy of Bimzelx has been demonstrated in phase 3 clinical trials, including BE VIVID, BE READY, and BE SURE. The results from these studies indicate that a substantial percentage of patients treated with Bimzelx achieved PASI 90 and PASI 100 responses within 16 weeks of treatment initiation. In some cases, improvements were observed as early as the first few weeks of therapy. These findings confirm that Bimzelx is an effective treatment option for patients with moderate to severe plaque psoriasis, providing significant skin clearance and improvement in disease symptoms.
Regulatory Agency Approvals
Ilumya
Bimzelx
Access Ilumya or Bimzelx today
If Ilumya or Bimzelx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us